lancemaside A: from Codonopsis lanceolata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Codonopsis | genus | A plant genus of the family CAMPANULACEAE. The common name of bellflower may sometimes be confused with other plants in the family that have similar appearance.[MeSH] | Campanulaceae | A plant family of the order Campanulales, subclass Asteridae, class Magnoliopsida[MeSH] |
Lancemaside A is a saponin that inhibits decreases in blood testosterone level and thus prevents or ameliorates symptoms associated with male climacteric disorder.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lancemaside A is a saponin that inhibits decreases in blood testosterone level and thus prevents or ameliorates symptoms associated with male climacteric disorder. " | ( Preparative separation of the saponin lancemaside a from Codonopsis lanceolata by centrifugal partition chromatography. Ichikawa, M; Komoto, N; Kuroyanagi, M; Nagamatsu, K; Ohta, S; Sekita, S; Shirota, O; Ushijima, M, ) | 1.85 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lancemaside A has a low bioavailability (1.1%) because of its metabolism by intestinal bacteria and its poor absorption in the gastrointestinal tract." | ( Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. Hayama, M; Ichikawa, M; Kodera, Y; Komoto, N; Kuroyanagi, M; Nakano, D; Nishihama, T; Ohta, S; Sekita, S; Shirota, O; Ushijima, M, 2010) | 1.36 |
Lancemaside A prevents hypertension in rats by inhibiting the activation of MAPK signalling and the impairment in nitric oxide bioavailability due to NOX2-mediated oxidative stress.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Lancemaside A has a low bioavailability (1." | ( Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. Hayama, M; Ichikawa, M; Kodera, Y; Komoto, N; Kuroyanagi, M; Nakano, D; Nishihama, T; Ohta, S; Sekita, S; Shirota, O; Ushijima, M, 2010) | 1.55 |
| "Lancemaside A prevents hypertension in rats by inhibiting the activation of MAPK signalling and the impairment in nitric oxide bioavailability due to NOX2-mediated oxidative stress." | ( Lancemaside A from Codonopsis lanceolata prevents hypertension by inhibiting NADPH oxidase 2-mediated MAPK signalling and improving NO bioavailability in rats. Han, AY; Hsieh, YS; Kim, J; Kwon, S; Lee, KW; Seol, GH; Shin, YK, 2019) | 3.4 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||